These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9690851)

  • 21. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azido- and isothiocyanato-substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction.
    Howlett AC; Wilken GH; Pigg JJ; Houston DB; Lan R; Liu Q; Makriyannis A
    J Neurochem; 2000 May; 74(5):2174-81. PubMed ID: 10800963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange.
    Kearn CS; Greenberg MJ; DiCamelli R; Kurzawa K; Hillard CJ
    J Neurochem; 1999 Jun; 72(6):2379-87. PubMed ID: 10349847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
    Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
    Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
    Bouaboula M; Perrachon S; Milligan L; Canat X; Rinaldi-Carmona M; Portier M; Barth F; Calandra B; Pecceu F; Lupker J; Maffrand JP; Le Fur G; Casellas P
    J Biol Chem; 1997 Aug; 272(35):22330-9. PubMed ID: 9268384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
    Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
    Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.
    Dennis I; Whalley BJ; Stephens GJ
    Br J Pharmacol; 2008 Jul; 154(6):1349-58. PubMed ID: 18493244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
    Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
    J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
    Rhee MH; Vogel Z; Barg J; Bayewitch M; Levy R; Hanus L; Breuer A; Mechoulam R
    J Med Chem; 1997 Sep; 40(20):3228-33. PubMed ID: 9379442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors.
    Glass M; Northup JK
    Mol Pharmacol; 1999 Dec; 56(6):1362-9. PubMed ID: 10570066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
    Petitet F; Jeantaud B; Capet M; Doble A
    Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
    Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
    Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice.
    Monory K; Tzavara ET; Lexime J; Ledent C; Parmentier M; Borsodi A; Hanoune J
    Biochem Biophys Res Commun; 2002 Mar; 292(1):231-5. PubMed ID: 11890697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.
    Wang L; Liu J; Harvey-White J; Zimmer A; Kunos G
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1393-8. PubMed ID: 12538878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells.
    Shryock JC; Ozeck MJ; Belardinelli L
    Mol Pharmacol; 1998 May; 53(5):886-93. PubMed ID: 9584215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of cannabinoid receptor agonist-stimulated [35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse.
    Basavarajappa BS; Hungund BL
    Brain Res; 1999 Jan; 815(1):89-97. PubMed ID: 9974126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system.
    Rinaldi-Carmona M; Le Duigou A; Oustric D; Barth F; Bouaboula M; Carayon P; Casellas P; Le Fur G
    J Pharmacol Exp Ther; 1998 Dec; 287(3):1038-47. PubMed ID: 9864290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
    Zhu J; Luo LY; Li JG; Chen C; Liu-Chen LY
    J Pharmacol Exp Ther; 1997 Aug; 282(2):676-84. PubMed ID: 9262330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
    Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
    J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
    Pertwee RG
    Life Sci; 2005 Feb; 76(12):1307-24. PubMed ID: 15670612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.